Sera Prognostics Inc

NASDAQ SERA

Download Data

Sera Prognostics Inc Interest Coverage Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -34.54%

Sera Prognostics Inc Interest Coverage Ratio 2 year CAGR is -34.54% for the Trailing 12 Months (TTM) ending March 31, 2024, a -105.69% change year over year. The interest coverage ratio is a measure of a company's ability to meet its interest payment obligations on its outstanding debt. It is calculated by dividing the company's earnings before interest and taxes (EBIT) by its interest expense. This ratio indicates the extent to which a company's earnings can cover its interest expenses. A higher interest coverage ratio suggests that the company has a greater capacity to make interest payments, indicating lower financial risk. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Sera Prognostics Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -618.04, a 73.75% change year over year.
  • Sera Prognostics Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -2,354.45, a -18,925.97% change year over year.
  • Sera Prognostics Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -12.37, a -26.97% change year over year.
  • Sera Prognostics Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -9.75.
NASDAQ: SERA

Sera Prognostics Inc

CEO Dr. Gregory C. Critchfield M.D., M.S.
IPO Date July 15, 2021
Location United States
Headquarters 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees 55
Sector Healthcare
Industry Diagnostics & research
Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Similar companies

FONR

Fonar Corporation

NA

NA

OLK

Olink Holding AB ADR

NA

NA

XGN

Exagen Inc

NA

NA

DRIO

DarioHealth Corp

NA

NA

PSNL

Personalis Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email